We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.43%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$240M
Cap. Flow
+$114M
Cap. Flow %
4.13%
Top 10 Hldgs %
48.06%
Holding
144
New
27
Increased
15
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$58.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$54.6M
3
JNJ icon
Johnson & Johnson
JNJ
+$45.1M
4
ALKS icon
Alkermes
ALKS
+$27.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$24.1M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$21.9M
3
PRGO icon
Perrigo
PRGO
+$21.6M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$19.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 84.12%
2 Real Estate 3.08%
3 Financials 1.53%
4 Technology 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STJ
51
DELISTED
St Jude Medical
STJ
$11.8M 0.43%
161,510
– –
SBRA icon
52
Sabra Healthcare REIT
SBRA
$5.38B
$11.7M 0.42%
456,190
– –
VTRS icon
53
CALL
Viatris
VTRS
$20.7B
$11.7M 0.42%
+172,400
New +$12.2M
TXMD icon
54
TherapeuticsMD
TXMD
$23.5M
$11.6M 0.42%
29,630
– –
TMO icon
55
Thermo Fisher Scientific
TMO
$214B
$11.2M 0.41%
86,395
-55,300
-39% -$7.21M
ZBH icon
56
Zimmer Biomet
ZBH
$18.4B
$11.2M 0.4%
105,369
– –
PVLA
57
Palvella Therapeutics
PVLA
$2.15B
$10.6M 0.38%
+48,102
New +$10.6M
MRK icon
58
Merck
MRK
$321B
$10.5M 0.38%
193,880
– –
CYTO
59
DELISTED
Altamira Therapeutics Ltd
CYTO
$10.4M 0.38%
+26
New +$10.8M
SGNT
60
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$9.96M 0.36%
409,500
– –
LTC
61
LTC Properties
LTC
$2.06B
$9.84M 0.36%
236,618
– –
CNC icon
62
Centene
CNC
$30.1B
$9.65M 0.35%
240,000
– –
THC icon
63
Tenet Healthcare
THC
$21.8B
$9.52M 0.34%
164,500
+105,000
+176% +$5.36M
VSTM icon
64
Verastem
VSTM
$536M
$9.42M 0.34%
104,152
– –
IRWD icon
65
Ironwood Pharmaceuticals
IRWD
$614M
$9.26M 0.34%
917,052
– –
ADYX
66
DELISTED
Adynxx Inc
ADYX
$8.7M 0.31%
+27,500
New +$8.13M
IDXX icon
67
Idexx Laboratories
IDXX
$44.1B
$8.49M 0.31%
132,352
+19,822
+18% +$1.37M
ELGX
68
DELISTED
Endologix Inc
ELGX
$8.45M 0.31%
55,100
– –
DHC
69
Diversified Healthcare Trust
DHC
$2.17B
$8.42M 0.3%
483,920
– –
WCG
70
DELISTED
Wellcare Health Plans, Inc.
WCG
$7.52M 0.27%
88,652
– –
ITCI
71
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.26M 0.26%
227,164
+77,164
+51% +$1.96M
MACK
72
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$7.02M 0.25%
72,166
– –
BLUE
73
DELISTED
bluebird bio
BLUE
$6.88M 0.25%
3,157
-1,052
-25% -$2.14M
ZGNX
74
DELISTED
Zogenix, Inc.
ZGNX
$6.38M 0.23%
475,101
+118,750
+33% +$1.46M
RARE icon
75
Ultragenyx Pharmaceutical
RARE
$2.56B
$6.14M 0.22%
+60,000
New +$4.66M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Tekla Capital Management held 144 positions worth $2.76B, up 9.5% from $2.52B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Tekla Capital Management deployed $114M of net new capital in Q2 2015, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Humana: 112,000 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was AbbVie, an estimated $72.5M trimmed.

  • Tekla Capital Management's largest Q2 2015 buy was Humana: 112,000 shares worth $21.4M.
  • Tekla Capital Management added most to Viatris in Q2 2015, an estimated $58.4M increase.
  • Tekla Capital Management's biggest Q2 2015 reduction was AbbVie, cutting an estimated $72.5M.
  • Tekla Capital Management fully exited Perrigo in Q2 2015, selling an estimated $21.6M.
  • Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q2 2015.
  • Tekla Capital Management opened 27 new positions and closed 28 in Q2 2015.
  • Tekla Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.